Loading content

Dr Byron Creese

Senior Research Fellow

RILD Building Level 4

My background is in psychology, which I studied to MSc level before undertaking my PhD in 2009 at King's College London in Prof Clive Ballard's group - my thesis examined the genetics of psychotic symptoms in Alzheimer's disease and Lewy body dementias. After a brief period working in the Government Statistical Service at the Home Office, I returned to King’s in 2014 where I resumed work on the management of several large cohort studies – setting up key international collaborations in doing so - which would ultimately feed into the genetics work I am leading at the University of Exeter.

Alongside my genetics work at King’s I played a key role in the setting up and management of the South London and Maudsley Care Home Research Network (affiliated with the NIHR Biomedical Research Centre at King’s). I have also worked on several important studies evaluating the effectiveness of various interventions for neuropsychiatric symptoms in dementia, including management of the NIHR-funded DCM-EPIC study in London and a clinical trial evaluating memantine for the long-term treatment of agitation in dementia.

Research

Research interests

I have a particular interest in using genome-wide data to understand the aetiology of neuropsychiatric symptoms in dementia and the overlap with other diseases across the lifespan (e.g. schizophrenia, major depressive disorder). I have set up several key international collaborations to work towards this aim, most notably at the University of Stavanger, the Norwegian Centre for Research, Education and Service Development and the University of Oslo. I am currently leading a project using genomic data to identify genes and molecular pathways associated with key neuropsychiatric symptoms in dementia with a view to identifying new treatment targets.

Alongside my genetics work I also have expertise in the setting up and management of complex research projects, cohort studies and clinical trials, having managed numerous project funded by industry, NIHR and charities.

Research projects

  • A genome-wide data driven approach to understanding the molecular mechanisms of psychosis and affective symptoms in dementia (two PhD projects: University of Exeter and King’s College London).
  • A systematic programme to develop and evaluate the best candidate treatments for repositioning in Alzheimer’s Disease (SMART-AD)
  • South London and the Maudsley Care Home Research Network
  • Helse Stavanger Care Home Research Network, Norway

Key publications | Publications by category | Publications by year

Publications by category


Journal articles

Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, Ballard C (2017). Cognitive decline in Parkinson disease. Nat Rev Neurol, 13(4), 217-231. Abstract.  Author URL.
Ffytche DH, Creese B, Politis M, Chaudhuri KR, Weintraub D, Ballard C, Aarsland D (2017). The psychosis spectrum in Parkinson disease. Nat Rev Neurol, 13(2), 81-95. Abstract.  Author URL.
Surr CA, Walwyn REA, Lilley-Kelly A, Cicero R, Meads D, Ballard C, Burton K, Chenoweth L, Corbett A, Creese B, et al (2016). Evaluating the effectiveness and cost-effectiveness of Dementia Care Mapping™ to enable person-centred care for people with dementia and their carers (DCM-EPIC) in care homes: study protocol for a randomised controlled trial. Trials, 17(1). Abstract.  Author URL.  Full text.
Ballard C, Thomas A, Gerry S, Yu L-M, Aarsland D, Merritt C, Corbett A, Davison C, Sharma N, Khan Z, et al (2015). A Double-Blind Randomized Placebo-Controlled Withdrawal Trial Comparing Memantine and Antipsychotics for the Long-Term Treatment of Function and Neuropsychiatric Symptoms in People with Alzheimer's Disease (MAIN-AD). JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 16(4), 316-322. Author URL.
Creese B, Ballard C, Aarsland D, Londos E, Sharp S, Jones E (2014). Determining the Association of the 5HTTLPR Polymorphism with Delusions and Hallucinations in Lewy Body Dementias. The American Journal of Geriatric Psychiatry, 22(6), 580-586.
Creese B, Corbett A, Jones E, Fox C, Ballard C (2014). Role of the Extended MAPT Haplotype in the Worsening of Psychotic Symptoms and Treatment Response in Alzheimer Disease. Journal of the American Medical Directors Association, 15(12), 934-937.
Creese B, Ballard C, Jones E (2013). Cognitive Impairment in Studies of 5HTTLPR and Psychosis in Alzheimer’s Disease: a Systematic Review. Dementia and Geriatric Cognitive Disorders, 35(3-4), 155-164.
Creese B, Ballard C, Aarsland D, Londos E, Sharp S, Jones E (2012). No association of COMT val158met polymorphism and psychotic symptoms in Lewy body dementias. Neuroscience Letters, 531(1), 1-4.
Corbett A, Smith J, Creese B, Ballard C (2012). Treatment of Behavioral and Psychological Symptoms of Alzheimer’s Disease. Current Treatment Options in Neurology, 14(2), 113-125.
Creese B, Ballard C, Corbett A, Aarsland D (2011). Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. Expert Opinion on Drug Safety, 10, 35-43.

Publications by year


2017

Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, Ballard C (2017). Cognitive decline in Parkinson disease. Nat Rev Neurol, 13(4), 217-231. Abstract.  Author URL.
Ffytche DH, Creese B, Politis M, Chaudhuri KR, Weintraub D, Ballard C, Aarsland D (2017). The psychosis spectrum in Parkinson disease. Nat Rev Neurol, 13(2), 81-95. Abstract.  Author URL.

2016

Surr CA, Walwyn REA, Lilley-Kelly A, Cicero R, Meads D, Ballard C, Burton K, Chenoweth L, Corbett A, Creese B, et al (2016). Evaluating the effectiveness and cost-effectiveness of Dementia Care Mapping™ to enable person-centred care for people with dementia and their carers (DCM-EPIC) in care homes: study protocol for a randomised controlled trial. Trials, 17(1). Abstract.  Author URL.  Full text.

2015

Ballard C, Thomas A, Gerry S, Yu L-M, Aarsland D, Merritt C, Corbett A, Davison C, Sharma N, Khan Z, et al (2015). A Double-Blind Randomized Placebo-Controlled Withdrawal Trial Comparing Memantine and Antipsychotics for the Long-Term Treatment of Function and Neuropsychiatric Symptoms in People with Alzheimer's Disease (MAIN-AD). JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 16(4), 316-322. Author URL.

2014

Creese B, Ballard C, Aarsland D, Londos E, Sharp S, Jones E (2014). Determining the Association of the 5HTTLPR Polymorphism with Delusions and Hallucinations in Lewy Body Dementias. The American Journal of Geriatric Psychiatry, 22(6), 580-586.
Creese B, Ballard C, Corbett A (2014). Influence of the Tau Haplotype on Progression and Treatment Response of Neuropsychiatric Symptoms in People with Alzheimer's Disease.  Abstract.
Creese B, Corbett A, Jones E, Fox C, Ballard C (2014). Role of the Extended MAPT Haplotype in the Worsening of Psychotic Symptoms and Treatment Response in Alzheimer Disease. Journal of the American Medical Directors Association, 15(12), 934-937.

2013

Creese B, Ballard C, Jones E (2013). Cognitive Impairment in Studies of 5HTTLPR and Psychosis in Alzheimer’s Disease: a Systematic Review. Dementia and Geriatric Cognitive Disorders, 35(3-4), 155-164.

2012

Creese B, Ballard C, Aarsland D, Londos E, Sharp S, Jones E (2012). No association of COMT val158met polymorphism and psychotic symptoms in Lewy body dementias. Neuroscience Letters, 531(1), 1-4.
Corbett A, Smith J, Creese B, Ballard C (2012). Treatment of Behavioral and Psychological Symptoms of Alzheimer’s Disease. Current Treatment Options in Neurology, 14(2), 113-125.

2011

Creese B, Ballard C, Corbett A, Aarsland D (2011). Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. Expert Opinion on Drug Safety, 10, 35-43.

Invited lectures

  • Aging and Health: Norwegian Centre for Research, Education and Service Development annual conference, Demensdagen (‘Dementia Days’), Oslo 7th December 2016.
  • Lewy bodies & Parkinson’s dementia: unmet needs & emerging treatments, South London and the Maudsley NIHR Biomedical Research Centre, London 12th April 2016.
  • Centre for Age-Realted Medicine (SESAM), Helse Stavanger annual conference, Norway 9th February 2015.

Back | Edit Profile